财务数据和关键指标变化 - 2024年第一季度总收入为5640万美元，较2023年同期的6300万美元下降 [39] - 研发费用为1亿零101万美元，较2023年同期的1亿5756万美元下降 [40] - SG&A费用为3630万美元，较2023年同期的4680万美元下降 [40] - 截至2024年第一季度，公司现金、现金等价物和投资总额为15.1亿美元，较2023年底的16.3亿美元下降1.18亿美元 [41] 各条业务线数据和关键指标变化 - 在SOLSTICE试验中，完成了超过60名参与者的入组，较预期提前一个月 [14][26] - 在SOLSTICE试验中，初步数据显示，六名参与者中有五名的HDV RNA未检测到，且所有参与者均低于定量下限 [25] 公司战略和发展方向和行业竞争 - 公司计划在2024年进行转型，专注于满足高未满足医疗需求的领域 [10] - 公司致力于开发针对慢性乙型肝炎的治疗方案，目标是实现30%或更高的功能性治愈率 [18] - 公司正在利用AI和机器学习优化抗体治疗的开发 [21] 管理层对经营环境和未来前景的评论 - 管理层认为2024年将是公司转型的重要一年，致力于为患者提供有效的治疗方案 [10] - 管理层对慢性乙型肝炎和慢性丙型肝炎的治疗前景表示乐观，认为有潜力显著改善患者的生活质量 [17][19] 其他重要信息 - 公司董事会提名了两位新独立董事，分别是诺伯特·比肖夫伯格博士和法里德博士 [6] - CFO宋李将在本周末辞职，管理层对其贡献表示感谢 [9] 问答环节所有提问和回答 问题: 关于HDV患者的基线肝硬化情况 - 公司表示在SOLSTICE试验中，包含了约50%的补偿性肝硬化患者，这将有助于评估治疗的安全性和有效性 [46] 问题: 关于ALT正常化的预期 - 公司认为在即将发布的数据中，可能会看到更多的ALT正常化情况，尤其是在更大样本量的情况下 [74] 问题: 关于HBV项目的表面抗原水平分组数据 - 公司确认将在HBV试验中分析不同表面抗原水平的患者数据，以评估其对治疗效果的影响 [71] 问题: 关于SOLSTICE试验的加速审批路径 - 公司表示将根据数据的强度寻求加速审批的可能性，包括快速通道和突破性疗法等机制 [70] 问题: 关于耐药性和疗效的持久性 - 公司认为基于目前的数据，耐药性的发展可能性较小，且预计不同机制的联合使用将降低耐药性风险 [66]

– $1.51 billion in cash, cash equivalents and investments as of March 31, 2024 – – Conference call scheduled for May 2, 2024 at 1:30 p.m. PT / 4:30 p.m. ET – SAN FRANCISCO, May 2, 2024 – Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. "We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming EASL congress. This milestone brings us closer to addressing the s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-K ________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 _____________ ...

Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Results Conference Call February 22, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Phil Pang - Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Nik Gasic - Leerink Partners Eva Privitera - TD Cowen Patrick Trucchio - H.C. Wainwright Eric Joseph - JP Morgan Alec Stranahan - Bank of America Joseph Stringer - Needha ...

Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results – Prior data from the Phase 2 SOLSTICE trial in chronic hepatitis delta participants demonstrated that after only 12 weeks of combination therapy, 100% (6/6) of participants had HDV RNA less than the lower limit of quantification – – Phase 2 SOLSTICE trial on track to complete enrollment ahead of schedule with initial data expected in the second quarter; greater than 90% of participants d ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________to Commission File Number: ...

Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Phil Pang - Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Patrick Trucchio - H. C. Wainwright Nik Gasic - Leerink Partners Eva Privitera - TD Cowen Joseph Stringer - Needham & Compan ...

© 2023 Vir Biotechnology, Inc. 1 NIR C O R P O R A T E O V E R V I E W Aug 2023 LEGAL DISCLAIMER Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the near-term financial performance of Vir Biotechnology, Inc. (the "Company" or "Vir"), the Company's strategy and plans; financial and operating results and its expectations related thereto; potent ...

FORM 10-Q __________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________ For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________to Commission File Number: 001- ...

Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - EVP and Chief Corporate Affairs Officer Marianne De Backer - CEO Phil Pang - CMO Sung Lee - CFO Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Roanna Ruiz - Leerink Partners Eric Joseph - JPMorgan Eva Privitera - TD Cowen Mike Ulz - Morgan Stanley Joseph Stringer - Needham & Company Patrick Trucchio - H.C. Wainwright Operator Hello. Welcome t ...